John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Resectable and borderline pancreatic cancer Volume 24, supplement 2, Juin 2017

Figures

  • Figure 1

Tables

Authors
1 Hôpitaux Universitaires Paris Nord Val de Seine (HUPNVS), Hôpital Beaujon, service d’oncologie digestive, 100 boulevard du Général Leclerc, 92110 Clichy-La-Garenne, France
2 Hôpital Bicêtre, service d’hépato-gastro-entérologie, Clamart, France
* Tirés à part

Whereas surgery remains the single potentially curative treatment of the pancreatic adenocarcinoma, its efficacy mainly depends the possibility to achieve a R0 resection, and this treatment is only possible for a minority of patients. In frontline resectable or borderline tumours, the quality of perioperative management is crucial. In neoadjuvant setting, a period of induction chemotherapy with or without radiation therapy administration is suitable in order to detect intrinsic tumour aggressivity and optimize the chance to achieve a R0 resection. Gemcitabine administration was the standard of adjuvant therapy while a recent study suggests an improved 5-year survival using a combination of this drug with capecitabine. In patients with resectable or borderline tumours, there a need of robust and prospective clinical trials in order to establish new standards of management.